213 related articles for article (PubMed ID: 19879698)
1. Hypofractionation: what does it mean for prostate cancer treatment?
Liao Y; Joiner M; Huang Y; Burmeister J
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):260-8. PubMed ID: 19879698
[TBL] [Abstract][Full Text] [Related]
2. Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate.
Luxton G; Hancock SL; Boyer AL
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):267-84. PubMed ID: 15093924
[TBL] [Abstract][Full Text] [Related]
3. Inclusion of a variable RBE into proton and photon plan comparison for various fractionation schedules in prostate radiation therapy.
Ödén J; Eriksson K; Toma-Dasu I
Med Phys; 2017 Mar; 44(3):810-822. PubMed ID: 28107554
[TBL] [Abstract][Full Text] [Related]
4. What hypofractionated protocols should be tested for prostate cancer?
Fowler JF; Ritter MA; Chappell RJ; Brenner DJ
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1093-104. PubMed ID: 12829147
[TBL] [Abstract][Full Text] [Related]
5. Late outcomes following hypofractionated conformal radiotherapy vs. standard fractionation for localized prostate cancer: a nonrandomized contemporary comparison.
Leborgne F; Fowler J
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1441-6. PubMed ID: 19395194
[TBL] [Abstract][Full Text] [Related]
6. Comparison of different fractionation schedules toward a single fraction in high-dose-rate brachytherapy as monotherapy for low-risk prostate cancer using 3-dimensional radiobiological models.
Mavroidis P; Milickovic N; Cruz WF; Tselis N; Karabis A; Stathakis S; Papanikolaou N; Zamboglou N; Baltas D
Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):216-23. PubMed ID: 24331667
[TBL] [Abstract][Full Text] [Related]
7. Modern hypofractionation schedules for tangential whole breast irradiation decrease the fraction size-corrected dose to the heart.
Appelt AL; Vogelius IR; Bentzen SM
Clin Oncol (R Coll Radiol); 2013 Mar; 25(3):147-52. PubMed ID: 22910644
[TBL] [Abstract][Full Text] [Related]
8. Higher-than-expected severe (Grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients.
Cozzarini C; Fiorino C; Deantoni C; Briganti A; Fodor A; La Macchia M; Noris Chiorda B; Rancoita PM; Suardi N; Zerbetto F; Calandrino R; Montorsi F; Di Muzio N
Eur Urol; 2014 Dec; 66(6):1024-30. PubMed ID: 24985964
[TBL] [Abstract][Full Text] [Related]
9. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
10. Designing equivalent treatment regimens for prostate radiotherapy based on equivalent uniform dose.
Li XA; Wang JZ; Stewart RD; Dibiase SJ; Wang D; Lawton CA
Br J Radiol; 2008 Jan; 81(961):59-68. PubMed ID: 18039721
[TBL] [Abstract][Full Text] [Related]
11. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning.
Sharfo AWM; Dirkx MLP; Bijman RG; Schillemans W; Breedveld S; Aluwini S; Pos F; Incrocci L; Heijmen BJM
Radiother Oncol; 2018 Aug; 128(2):349-356. PubMed ID: 29885745
[TBL] [Abstract][Full Text] [Related]
12. The impact of geometric uncertainty on hypofractionated external beam radiation therapy of prostate cancer.
Craig T; Moiseenko V; Battista J; Van Dyk J
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):833-42. PubMed ID: 14529791
[TBL] [Abstract][Full Text] [Related]
13. Optimization of radiotherapy fractionation schedules based on radiobiological functions.
Pizarro F; Hernández A
Br J Radiol; 2017 Nov; 90(1079):20170400. PubMed ID: 28830219
[TBL] [Abstract][Full Text] [Related]
14. The radiobiology of hypofractionation.
Nahum AE
Clin Oncol (R Coll Radiol); 2015 May; 27(5):260-9. PubMed ID: 25797579
[TBL] [Abstract][Full Text] [Related]
15. Risk-adaptive optimization: selective boosting of high-risk tumor subvolumes.
Kim Y; Tomé WA
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1528-42. PubMed ID: 17126211
[TBL] [Abstract][Full Text] [Related]
16. Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer.
Li XA; Wang JZ; Jursinic PA; Lawton CA; Wang D
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1251-7. PubMed ID: 15752907
[TBL] [Abstract][Full Text] [Related]
17. Impact of tumor repopulation on radiotherapy planning.
Wang JZ; Li XA
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):220-7. PubMed ID: 15629615
[TBL] [Abstract][Full Text] [Related]
18. Fitting tumor control probability models to biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer: pitfalls in deducing radiobiologic parameters for tumors from clinical data.
Levegrün S; Jackson A; Zelefsky MJ; Skwarchuk MW; Venkatraman ES; Schlegel W; Fuks Z; Leibel SA; Ling CC
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):1064-80. PubMed ID: 11704332
[TBL] [Abstract][Full Text] [Related]
19. Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer.
Strigari L; Arcangeli G; Arcangeli S; Benassi M
Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1454-60. PubMed ID: 18990503
[TBL] [Abstract][Full Text] [Related]
20. Later outcomes and alpha/beta estimate from hypofractionated conformal three-dimensional radiotherapy versus standard fractionation for localized prostate cancer.
Leborgne F; Fowler J; Leborgne JH; Mezzera J
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1200-7. PubMed ID: 21477933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
